Skip to main content

Tweets

Can Mycophenolate be Stopped in Stable SLE? https://t.co/8oQx0cqDr3 https://t.co/mlt2Qqj8wm
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
COVIDs Extended Risk for Rheumatic Disease Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for AIRDs that extends up to 12 months after infection. https://t.co/HjQ56hiiny https://t.co/vvC3iVqNyF
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
Review of autoimmune Dz & adverse preg outcomes: Incr risk of: - Miscarriage w/ Sjögrens (RR 8.85) & SLE (OR 4.9) - Preeclampsia w/ SLE (OR 3.2) - IUGR w/ scleroderma (OR 3.2) & celiac (OR 1.71) - Preterm birth w/ SLE (OR 2.79). https://t.co/bll2x2aS9Z https://t.co/Eg0sVBcPmR
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/Spb0ABOMMm https://t.co/wkMurvB0G3
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Lancet - Full Read Review of the Diagnosis and management of ANCA-associated vasculitis by Stone, et al https://t.co/Lg0FKR8RZ4 https://t.co/RUpK00YmTh
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity #1 (24%) w/ RP-ILD & high mortality #2 (14%) dermatomyositis, intermediate prognosis #3 (62%) arthritis & mechanics hands, good prognosis https://t.co/4NqZp4yR18 https://t.co/rBrhBxxniR
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
ICYMI: Community-Acquired Pneumonia (CAP) https://t.co/AMConIb14r https://t.co/BCfcHc5i37
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/a3XeAa2lcG https://t.co/dTZa2uQF97
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 6 days ago
Polyautoimmunity in RA, Regardless of ACPA Positivity While it is believed that autoimmunity follows autoantibody positivity, a Danish study shows the incidence of polyautoimmunity to be similar in RA patients who are either ACPA + or -. https://t.co/7lmp1NB0XX https://t.co/onaEluzkGy
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 6 days ago
19% Arthritis Prevalence in the US According to NHIS, in 2022, the prevalence of diagnosed arthritis in adults was 18.9% . These numbers are down since the CDC's MMWR report of 2019–'21, where it was estimated 21.2% of U.S. adults had "diagnosed arthritis" https://t.co/mtYSBHw8Oo https://t.co/NHqjLlwatm
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 6 days ago
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/cdSVbuBzXf https://t.co/CUC5v0hSxr
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 6 days ago
Fibroblast activation w/ inflammatory arthritis studied by PET to detect fibroblast activation protein (FAP), but decreases after TNF or 17A inhib. Fibroblasts switch from pathogenic (MMP3+/IL6+) to pro-resolving phenotype (CD200+DKK3+) https://t.co/K1xAMqPiuT https://t.co/07NNgW9Lpv
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 6 days ago